Oncotelic Updates Pipeline While Honoring CEO Dr. Vuong Trieu’s Industry-Changing Legacy

Oncotelic Therapeutics, Inc., a clinical-stage biopharma company advancing oncology and immunotherapy treatments, has shared an update on its clinical pipeline while spotlighting the achievements of its Chairman and CEO, Dr. Vuong Trieu. Globally recognized for his intellectual property leadership, Dr. Trieu holds more than 500 filed patents and 75 issued patents spanning biologics, small molecules, nanoparticles, and diagnostics. His inventions have led to several FDA-approved or late-stage therapies, including the co-invention and development of Abraxane® (nab-paclitaxel), which was acquired by Celgene in a $2.9 billion transaction, and Cynviloq™, sold to NantPharma for $1.3 billion.

Dr. Trieu’s career contributions span multiple therapeutic areas such as oncology, cardiovascular disease, neuro-critical care, aging, and rare diseases. His track record reflects a consistent focus on developing first-in-class therapeutics that address areas of high unmet medical need. Oncotelic’s current pipeline is a testament to this vision, leveraging cutting-edge approaches to tackle both prevalent and rare diseases.

"Our strength lies not only in OTLC's clinical pipeline but also in the breadth of intellectual property generated over my career, converting deep tumour-microenvironment biology into globally protected, clinic-ready technologies that redefine how drugs are delivered, monitored, and personalised. We remain committed to transforming these innovations into life-saving therapies for patients and long-term value for shareholders," said Dr. Trieu. 

The company’s pipeline includes: OT-101, a TGF-β inhibitor in Phase 3 trials for pancreatic cancer and being studied in ARDS/COVID-19; OXi4503, a vascular disrupting agent in Phase 2 for AML/MDS moving toward pivotal Phase 3 design; CA4P (Fosbretabulin), a late-stage oncology asset under repositioning; AL-101, an intranasal apomorphine in Phase 2 for Parkinson’s and sexual dysfunctions; AL-102, an antisense oligonucleotide in discovery for Alzheimer’s disease; and a suite of pediatric rare disease programs targeting orphan indications with the potential to secure Priority Review Vouchers (PRVs). These programs, built on Dr. Trieu’s innovations, reinforce Oncotelic’s strategy of creating value through differentiated, IP-driven assets with strong competitive barriers.